艾洛普林醇可以改善慢性心力衰竭中的内皮功能障碍
Colin A J Farquharson1, Robert Butler, Alexander Hill
1Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK.
Circulation
|July 10, 2002
概括
在慢性心力衰竭患者中,阿洛普林醇通过减少氧化应激显著改善了内皮功能障碍. 这表明对心血管事件和运动能力有潜在的益处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 氧化压力研究研究 氧化压力研究
背景情况:
- 氧化应激与慢性心力衰竭中的内皮功能障碍有关.
- 丁氧化酶是产生氧化应激的关键酶.
研究的目的:
- 为了研究皮醇对慢性心力衰竭中的内皮功能障碍的影响.
- 确定艾洛普里诺尔是否能降低这些患者的氧化应激标志物.
主要方法:
- 这是一项随机,安慰剂控制,双盲交叉研究,涉及11名患有慢性心力衰竭的患者 (纽约心脏协会II-III类).
- 患者每天接受300毫克的阿洛普林诺或安慰剂一个月.
- 使用前臂静脉封闭囊扫描用乙胆,尼托普鲁西德和维拉帕米尔评估内皮功能.
- 血中马隆迪甲水平被测量为氧化应激的标志物.
主要成果:
- 与安慰剂相比,阿洛普林醇显著提高了对乙胆的前臂血流反应 (181+/-19%与120+/-22%,P=0.003).
- 在治疗组之间对尼托普鲁塞德或维拉帕米尔的反应没有发现显著差异.
- 艾洛普林醇治疗导致血中马隆迪化物水平显著降低 (346+/-128 nmol/L与461+/-101 nmol/L,P=0.03),表明氧化应激减少.
结论:
- 在慢性心力衰竭患者中,阿洛普林醇有效改善内皮功能障碍.
- 这些发现表明,在这种患者群体中,阿洛普林醇可能在减少心血管事件和增强运动能力方面提供治疗效益.
相关概念视频
Ligand-gated Ion Channels
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
